Compare Novo Nordisk A/S (NVO) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Visa Inc — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Visa Inc trades at $356.3 (market cap $685.71B). The key difference: Visa Inc is far larger — about 3.1× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | V | |
|---|---|---|
Market Cap | $220.53B | $685.71B |
Sector | Health | Financials |
52-Week High | $71.70 | $365.14 |
52-Week Low | $35.29 | $295.52 |
Enterprise Value | $239.49B | $696.30B |
Dividend Yield | 3.63% | 0.74% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Visa (V) trades at $355.82, down 0.76% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $396.70. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.31 exceeding expectations. Revenue reached $40 billion in 2025, and net income margin stands at 51.68%, reflecting robust profitability. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for future growth in digital payments.
Visa presents a favorable long-term investment opportunity due to its dominant market position, consistent earnings growth, and high profitability. Key risks include competitive pressures from fintech and regulatory scrutiny. With 85% of analysts rating it a buy and institutional ownership increasing, the stock offers upside potential, though investors should monitor execution on AI initiatives and macroeconomic factors affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
